All posts by: Michael Zand

About Michael Zand

BrainStorm gets FDA fast-track status for ALS stem cell therapy – Raw Story

Continue reading

2014-10-07 NEWS

Raw Story

BrainStorm gets FDA fast-track status for ALS stem cell therapy
Raw Story
Israel’s BrainStorm Cell Therapeutics said the U.S. Food and Drug Administration has designated its adult stem cell treatment as a “fast-track” product for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm’s treatment, called NurOwn, is
Brainstorm’s Stem Cell Based Drug NurOwn Gets FDA Fast Track ApprovalJewish Business News

all 28 news articles »

Continue reading

2014-10-07 NEWS

BrainStorm Gets FDA Fast-track Status For ALS Stem Cell Therapy
Business Insider
TEL AVIV (Reuters) – Israel’s BrainStorm Cell Therapeutics said the U.S. Food and Drug Administration has designated its adult stem cell treatment as a “fast-track” product for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm’s

and more »

Continue reading

2014-10-07 NEWS

BrainStorm Gets FDA Fast-track Status For ALS Stem Cell Therapy
Business Insider
TEL AVIV (Reuters) – Israel’s BrainStorm Cell Therapeutics said the U.S. Food and Drug Administration has designated its adult stem cell treatment as a “fast-track” product for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm’s

and more »

Continue reading

2014-10-07 NEWS

BrainStorm gets FDA fast-track status for ALS stem cell therapy
Reuters
TEL AVIV (Reuters) – Israel’s BrainStorm Cell Therapeutics said the U.S. Food and Drug Administration has designated its adult stem cell treatment as a “fast-track” product for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm’s

and more »